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Pathologic Outcomes in Men with Low-risk Prostate Cancer Who 
Are Potential Candidates for Contemporary, Active Surveillance 
Protocols
The purpose of this study was to determine whether contemporary active surveillance (AS) 
protocols could sufficiently discriminate significant from indolent tumors in men with low-
risk prostate cancer. We retrospectively analyzed 312 patients with low-risk prostate cancer 
treated with radical prostatectomy. After exclusion of patients with fewer than 10 cores 
taken at biopsy and those who received neo-adjuvant treatment, 205 subjects satisfied the 
final inclusion criteria. Five widely accepted AS protocols were employed in this study. A 
total of 82.0% of the patients met the inclusion criteria of at least one protocol, and 18% 
did not meet any criteria of published AS protocols. A significant proportion of patients 
had non-organ-confined disease (8.6% to 10.6%) or a Gleason score of 7 or greater 
(18.6% to 23.9%) between the different AS criteria. Among patients who did not meet 
any AS criteria, 32.4% of patients had a pathologically insignificant cancer. Our results 
indicated a significant adverse pathology in patients who met the contemporary AS 
protocols. On the other hand, some patients in whom expectant management would be 
appropriate did not meet any criteria of published AS protocols. None of the clinical or 
histological criteria reported to date is able to sufficiently discriminate aggressive tumors 
from indolent ones. 
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INTRODUCTION
Active surveillance (AS) is an emerging treatment strategy for 
low-risk prostate cancer (PCa) in response to high rates of over-
diagnosis using prostate-specific antigen (PSA) levels as a bio-
marker (1, 2). AS programs are designed to identify patients with 
clinically indolent tumors and to avoid or delay definitive treat-
ment in these men (3, 4). While AS appears to be a reasonable 
approach for insignificant tumors, its widespread acceptance 
remains limited by a lack of consensus in defining appropriate 
candidates (5). Inclusion criteria for currently used AS guide-
lines are usually based on the maximum Gleason score, PSA 
levels and/or PSA density, clinical stage, number of positive bi-
opsy cores, and percentage of single core involvement (6, 7). 
Currently, various criteria predicting potentially insignificant 
disease have attempted to strike a balance between maximiz-
ing the number of patients who can avoid treatment and mini-
mizing the number of aggressive cases (3, 4, 8, 9). While consid-
erable effort has been devoted to identifying an optimal AS cri-
teria in a clinical practice, adverse pathological features at radi-
cal prostatectomy have been reported in 11%-33.5% of potential 
candidates for AS (10, 11). In addition, most of AS studies do 
not yet have emphasized the risk of unintended exclusion of 
actual insignificant PCa. To address these questions, we com-
pared the discriminative performance of contemporary AS cri-
teria to determine whether contemporary AS protocols could 
sufficiently discriminate clinically significant from indolent tu-
mors in a cohort of low-risk PCa. Specifically, we also assessed 
the clinical and biopsy characteristics of pathologically insignif-
icant PCa patients who are not eligible for any criteria of pub-
lished AS protocols. 
MATERIALS AND METHODS
Study design
We retrospectively analyzed 312 patients with low-risk PCa treat-
ed with radical prostatectomy by a single surgeon at Severance 
Hospital between January 2007 and December 2013. Low-risk 
PCa was defined as clinical stage T1c/T2a, PSA levels of 10 ng/
mL or less, and a Gleason score of 6 or less on a multi-core bi-
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opsy according to the D’Amico classification. After exclusion of 
patients with fewer than 10 cores taken at biopsy and who re-
ceived neo-adjuvant treatment, 205 subjects satisfied the final 
inclusion criteria. We identified patients’ eligibility for the inclu-
sion criteria using five AS protocols: Johns Hopkins Medical In-
stitution (JHMI) (12), Memorial Sloan-Kettering Cancer Center 
(MSKCC) (13), Prostate Cancer Research International Active 
Surveillance (PRIAS) (14), University of California, San Francis-
co (UCSF) (15), and University of Miami (UM) (16). Adverse 
findings were Gleason score upgrade (score 7 or greater) and 
non-organ-confined cancer on surgical pathology. Pathologi-
cally insignificant PCa was defined as being organ-confined with 
a Gleason score less than or equal to 6 (no Gleason pattern 4/5) 
and a tumor volume less than 0.5 cm3 (8).
Statistical analysis
 Continuous variables are shown as the median and interquar-
tile range (IQR). The sensitivity, specificity, and accuracy of pa-
thologically insignificant PCa predictions between each AS cri-
teria were compared. Sensitivities, specificities, and diagnostic 
accuracy were calculated using standard formulas: sensitivity =  
TP/TP+FN; specificity = TN/TN+FP; and accuracy = TP+TN/ 
TP+TN+FP+FN, where TP is the number of true positives, TN is 
the number of true negatives, FP is the number of false positives, 
and FN is the number of false negatives. Analysis was perform-
ed using SPSS 20.0 software (SPSS Inc., Chicago, IL, USA).
Ethics statement
The study was carried out in agreement with applicable laws 
and regulations, good clinical practices, and ethical principles 
as described in the Declaration of Helsinki. The institutional re-
view board of Severance Hospital approved the present study 
protocol (Approval number: 4-2014-0619). 
RESULTS
Table 1 summarizes the baseline characteristics of the 205 low-
risk PCa patients included in the analysis. The median prebiop-
sy PSA and prostate-specific antigen density were 5.4 ng/mL 
(IQR 4.3-6.9 ng/mL) and 0.16 ng/mL/g (IQR 0.11-0.23 ng/mL/
g), respectively. The majority of men had a biopsy Gleason score 
of 6 and clinical T1c or T2a disease at the time of diagnosis. 
 After radical prostatectomy, 61 (29.8%) patients had their dis-
ease upgraded in the prostatectomy specimen (5 were upgrad-
ed to a Gleason score of 6, 50 were upgraded to a Gleason score 
of 3+4, 4 were upgraded to a Gleason score of 4+3, and 2 were 
upgraded to a Gleason score of 8) and 26 (12.7%) had non-or-
gan-confined disease (Table 2). The rates of adverse pathology 
in patients who qualified for each AS protocol are listed in Table 
3. A total of 82% of the patients fulfilled the inclusion criteria of 
at least one protocol, whereas 18% did not meet any criteria of 
contemporary five AS protocols. The JHMI protocol was the most 
stringent, with only 34.1% of the patients fulfilling the JHMI cri-
teria, whereas the MSKCC protocol was the most lenient, with 
Table 1. Characteristics of clinicopathological patients 
Characteristics Value
No. of patients 205
Mean age (IQR), (yr)  62.0 (57.0-67.0)
Median BMI (IQR), (kg/m2) 24.5 (22.8-25.9)
Median PSA (IQR), (ng/mL) 5.4 (4.3-6.9)
Median prostate volume (IQR), (mL) 31.5 (25.7-44.1)
Median PSA density (IQR), (ng/mL/cm3) 0.16 (0.11-0.23)
Median ratio of positive cores (IQR), (%) 10.0 (8.3-21.5)
Median ratio of cancer extent (IQR), (%) 20.0 (10.0-40.0)
Biopsy gleason score (%)
   5
   6
5 (2.4)
200 (97.6)
Clinical T stage, number (%)
   T1c
   T2a
118 (57.6)
87 (42.4)
Surgical methods, number (%)
   Open radical prostatectomy
   Robot-assisted laparoscopic radical prostatectomy
       Transperitoneal approach
       Extraperitoneal approach
9 (4.4)
12 (5.9)
184 (89.7)
IQR, interquartile range; PSA, prostate-specific antigen.
Table 2. Pathological outcomes of the study cohort
Characteristics Number (%)
High-grade PIN 111 (54.1)
Lymphovascular invasion 3 (1.5)
Perineural invasion 55 (26.8)
Pathologic gleason score
   6
   7 
   8
149 (72.7)
54 (26.3)
2 (1.0)
Pathologic T stage 
   T2a
   T2b
   T2c
   T3a
   T3b
39 (19.0)
54 (26.3)
86 (42.0)
23 (11.2)
3 (1.5)
Positive surgical margin 14 (6.8)
PIN, prostatic intraepithelial neoplasia.
Table 3. The rates of adverse pathology in patients who were qualified for active sur-
veillance criteria
Criteria No. of patients
Adverse pathological outcomes, number (%)
Gleason score ≥ 7 Non-OCD
JHMI   70 13 (18.6) 6 (8.6)
MSKCC 161 37 (23.0) 17 (10.6)
PRIAS 109 26 (23.9) 10 (9.2)
UCSF 141 33 (23.4) 14 (9.9)
UM   96 22 (22.9) 10 (10.4)
OCD, organ-confined disease; JHMI, Johns Hopkins Medical Institution; MSKCC, Me-
morial Sloan-Kettering Cancer Center; PRIAS, Prostate Cancer Research International: 
Active Surveillance; UCSF, University of California, San Francisco; UM, University of 
Miami.
Kang HW, et al. • Adverse Pathology of Prostate Cancer in Potential Candidates for Surveillance
934  http://jkms.org http://dx.doi.org/10.3346/jkms.2015.30.7.932
78.5% of the patients fulfilling the MSKCC criteria. For the PRIAS, 
UCSF, and UM criteria, 53.2%, 68.8%, and 46.8% of patients ful-
filled these criteria, respectively. Non-organ-confined disease 
was found in 8.6% to 10.6% of patients, and a Gleason score of 7 
or greater disease was found in 18.6% to 23.9% of patients ac-
cording to the five AS protocols.
 Overall, 135 patients (65.9%) had pathologically insignificant 
PCa. The abilities of each AS protocols to predict pathologically 
insignificant PCa are described in Table 4. The JHMI protocol 
showed the highest specificity but lowest sensitivity, whereas 
the MSKCC protocol showed the highest sensitivity but lowest 
specificity. Among patients who did not meet any criteria of con-
temporary five AS protocols, 12 (32.4%) patients had pathologi-
cally insignificant cancer (Table 5). There were no significant 
clinical and biopsy characteristics, which can discriminate path-
ologically significant from insignificant tumors in a cohort of 12 
patients who are not eligible for any criteria of contemporary 
five AS protocols (data not shown). During the median follow 
up of 47 (IQR: 25-72) months, only six patients (2.9%) had a bio-
chemical recurrence. There was no case of cancer-specific death. 
DISCUSSION
The present study investigated the pathologic outcomes in men 
with low-risk PCa who were potential candidates for contem-
porary AS protocols. Significant adverse pathology was identi-
fied in patients deemed eligible for contemporary AS protocols, 
but also some patients in whom expectant management would 
be appropriate are not eligible for any criteria of contemporary 
five AS protocols. Our results suggest the limited value of cur-
rently obtained histological criteria to appropriately select can-
didates for AS. 
 Currently, many different criteria of AS protocols are in use, 
ranging from stringent exclusive criteria to less stringent inclu-
sive criteria (6). Given the current status of numerous AS guide-
lines with no uniformly accepted standard, no current criteria 
sufficiently discriminate clinically significant from indolent tu-
mors. Several retrospective studies have emphasized the risk of 
under-diagnosis (17-20). Even with the most stringent selection 
criteria, it may be difficult to perfectly differentiate between clin-
ically insignificant and life-threatening PCa (10, 21). Several au-
thors have analyzed the pathologic features of surgical specimens 
in patients who qualified for different criteria of AS protocols. 
The discriminative ability of contemporary AS protocols show ed 
significant variation across different institutions (8, 11, 22-24). 
In a recent study by Iremashvili al., five AS protocols were com-
pared with regard to discriminative ability to predict three path-
ologic end points in a 391 radical prostatectomy cases. In this 
study, PRIAS and UM have demonstrated the highest ability to 
identify patients with insignificant prostate cancer (8). Lee et al. 
also compared the discriminative ability of five AS protocols and 
concluded that the PRIAS had the best balance between sensi-
Table 4. The ability of each active surveillance criterion to identify patients with patho-
logically insignificant prostate cancer
Criteria
Included  
patients
Pathologically insignificant prostate cancer
No (%) Sensitivity Specificity Accuracy 
Total cohort 205 135 (65.9)
Separate criteria
   JHMI
   MSKCC
   PRIAS
   UCSF
   UM
  70
161
109
141
  96
 55 (78.6)
119 (73.9)
 79 (72.5)
104 (73.8)
 72 (75.0)
40.7
88.1
58.5
77.0
53.3
78.6
40.0
57.1
47.1
65.7
53.7
71.7
58.0
66.8
57.6
Combined criteria
   All
   Any
   None
  29
168
  37
24 (82.8)
123 (73.2)
 12 (32.4)
JHMI, Johns Hopkins Medical Institution; MSKCC, Memorial Sloan-Kettering Cancer 
Center; PRIAS, Prostate Cancer Research International: Active Surveillance; UCSF, Uni-
versity of California, San Francisco; UM, University of Miami.
Table 5. Clinical and biopsy parameters of pathologically insignificant prostate cancer patients who did not meet any criteria of contemporary five AS protocols
Case number
Clinical and biopsy parameters Pathological results
PSA  
(ng/mL)
PSAD  
(ng/mL)
Ratio of positive cores 
(%)
Ratio of cancer 
extent (%)
bGS Clinical T stage pGS T stage
Tumor volume 
(cc)
  1 3.97 0.13 35.71 (5/14) 80 6.00 1c 6.00 2c 0.4
  2 3.84 0.09 41.67 (5/12) 60 6.00 1c 6.00 2a 0.2
  3 6.20 0.21 10.00 (1/10) 80 6.00 2a 6.00 2b 0.3
  4 6.96 0.26 16.67 (2/12) 70 6.00 2a 6.00 2b 0.3
  5 4.58 0.22 36.36 (4/11) 70 6.00 2a 6.00 2b 0.3
  6 6.06 0.20 30.00 (3/10) 70 6.00 1c 6.00 2c 0.1
  7 6.71 0.23 41.67 (5/12) 60 6.00 2a 6.00 2c 0.4
  8 6.11 0.10 25.00 (3/12) 60 6.00 2a 6.00 2b 0.3
  9 4.30 0.26 33.33 (4/12) 30 6.00 1c 6.00 2c 0.1
10 9.41 0.52 50.00 (5/10)   5 6.00 2a 6.00 2c 0.2
11 8.29 0.09 40.00 (4/10) 30 6.00 1c 6.00 2a 0.3
12 6.74 0.15 33.33 (4/12) 20 6.00 1c 6.00 2b 0.3
PSA, prostate-specific antigen; PSAD, prostate-specific antigen density; bGS, biopsy Gleason score; pGS, pathologic Gleason score.
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tivity, specificity and the diagnostic accuracy (11). Our results 
were similar to those described in previous studies in which sig-
nificant variations exist in the ability of contemporary AS proto-
cols to predict pathologically insignificant PCa. While numerous 
investigators described the ability of contemporary AS protocols 
to predict pathologically insignificant PCa, little is known about 
the possible exclusion of actual insignificant PCa. Interestingly, 
32.4% of patients who did not meet any AS criteria contemporary 
AS protocols had a pathologically insignificant cancer. These 
results suggested that none of the currently used clinical or his-
tological criteria have a sufficient sensitivity or specificity for the 
appropriate selection of candidates for AS (25). Consequently, 
there is a great needs for novel tools such as repeat biopsy, multi-
parametric magnetic resonance imaging and various blood mar-
kers (PSA isoform/kinetics), or others to blend into selection 
criteria on active surveillance for low-risk prostate cancer.
 Our study has both limitations and strengths. It had a retro-
spective design, which may have introduced some sampling 
bias. In addition, our study cohorts were consisted of low-risk 
PCa according to the D’Amico classification, which could be a 
confounding factor affecting discriminative performance. There-
fore, our results should be viewed as a comprehensive consid-
eration of contemporary AS criteria. On the other hand, our data 
originated from a single institution and a single surgeon, which 
minimizing performance variability and bias.
 In conclusion, significant adverse pathology was identified in 
patients deemed eligible for contemporary AS criteria. On the 
other hand, some patients in whom expectant management 
would be appropriate did not meet any AS criteria. These find-
ings suggest that none of the clinical or histological criteria re-
ported to date is able to sufficiently discriminate aggressive tu-
mors from indolent ones.
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